Literature DB >> 8430979

Estrogen protection against bone resorbing effects of parathyroid hormone infusion. Assessment by use of biochemical markers.

F Cosman1, V Shen, F Xie, M Seibel, A Ratcliffe, R Lindsay.   

Abstract

OBJECTIVE: Because parathyroid hormone (PTH) stimulates bone resorption, resistance to its actions might help maintain bone mass. We tested the hypothesis that the effects of estrogen on bone are accomplished in part by decreasing the sensitivity of the skeleton to the resorbing effects of PTH. STUDY
DESIGN: Comparison of response to PTH infusion in untreated and estrogen-treated postmenopausal women with osteoporosis. INTERVENTION: (1-34) human PTH, 0.55 U/(kg.h), was infused intravenously over 20 hours.
SETTING: The inpatient clinical research unit of a referral hospital. PATIENTS: Women with primary postmenopausal osteoporosis who were untreated (n = 15) or treated with estrogen (n = 17). MAIN OUTCOME MEASURES: Skeletal turnover indices including hydroxyproline, deoxypyridinoline, pyridinoline, tartrate-resistant acid phosphatase, alkaline phosphatase, bone Gla protein, and insulin-like growth factor-1.
RESULTS: All basal indices were higher in untreated than in estrogen-treated women, but statistical differences were seen only for deoxypyridinoline and pyridinoline. During the 20-hour infusion, hydroxyproline/creatinine increased 0.023 mumol/mumol in untreated women but only 0.010 mumol/mumol in estrogen-treated women (P < 0.05). Corresponding changes for deoxypyridinoline/creatinine were 14.6 mumol/mumol and 3.5 mumol/mumol (P = 0.06). Tartrate-resistant acid phosphatase and pyridinoline increased only in untreated group. A circadian rhythm in circulating bone Gla protein was seen in both groups without clear PTH-induced effects or differences between groups. Alkaline phosphatase levels decreased and insulin-like growth factor-1 levels increased in both groups with no distinction between untreated and estrogen-treated women [corrected].
CONCLUSION: The estrogenized postmenopausal osteoporotic skeleton is less sensitive to the bone resorbing effects of acutely administered PTH. There are no differential effects on bone formation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8430979     DOI: 10.7326/0003-4819-118-5-199303010-00003

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  24 in total

Review 1.  The selective oestrogen receptor modulation: evolution and clinical applications.

Authors:  D W Purdie; S A Beardsworth
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

2.  Demographic, dietary, and serum factors and parathyroid hormone in the National Health and Nutrition Examination Survey.

Authors:  J M Paik; W R Farwell; E N Taylor
Journal:  Osteoporos Int       Date:  2011-09-20       Impact factor: 4.507

3.  Regulation of the gp80 and gp130 subunits of the IL-6 receptor by sex steroids in the murine bone marrow.

Authors:  S C Lin; T Yamate; Y Taguchi; V Z Borba; G Girasole; C A O'Brien; T Bellido; E Abe; S C Manolagas
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Increased PTHrP and decreased estrogens alter bone turnover but do not reproduce the full effects of lactation on the skeleton.

Authors:  Laleh Ardeshirpour; Susan Brian; Pamela Dann; Joshua VanHouten; John Wysolmerski
Journal:  Endocrinology       Date:  2010-11-03       Impact factor: 4.736

5.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

Review 6.  Role of bone-forming agents in the management of osteoporosis.

Authors:  Michael R McClung
Journal:  Aging Clin Exp Res       Date:  2021-02-16       Impact factor: 3.636

Review 7.  Normocalcemic primary hyperparathyroidism.

Authors:  Natalie E Cusano; Shonni J Silverberg; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

Review 8.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

9.  Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitrophic hormones.

Authors:  J F Aloia; A Vaswani; J K Yeh; L Russo
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

10.  Indirect regulation of PTH by estrogens may require FGF23.

Authors:  Natalia Carrillo-López; Pablo Román-García; Ana Rodríguez-Rebollar; José Luis Fernández-Martín; Manuel Naves-Díaz; Jorge B Cannata-Andía
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.